Shares of Recursion Pharmaceuticals are down by about 47% from a peak the stock set this February. The company uses automation and artificial intelligence to optimize the new drug-discovery process.

Eli Lilly is a well-established pharmaceutical company with a portfolio of products that consistently generate revenue and earnings. The company's top line has been growing at a good clip in recent ...

Recursion Pharmaceuticals (RXRX) shares rallied 7.4% in the last trading session to close at $11.93. This move can be attributable to notable volume with a higher number of shares being traded than in ...